Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Subjects
Brief Summary: The purpose of this study is to investigate the efficacy and safety of TMC435 plus PSI-7977 (GS7977) with or without ribavirin in patients who are chronically infected with genotype 1 hepatitis C virus (HCV) and who did not respond to prior peginterferon/ribavirin therapy or are HCV treatment-naive (patients who never received treatment for HCV infection).


Options:
A: Arm Label: Velpatasvir 5 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 100 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1b); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 4); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir up to 400 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Velpatasvir; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2)
B: Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Placebo for Ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV, ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus RBV | Intervention Type: DRUG; Name: Placebo for Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977), Drug: Ribavirin | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PSI-7977 (GS7977) | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: PSI-7977 (GS7977); Assigned to Arm(s): Arm 1, Arm 2, Arm 3, Arm 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Arm 1, Arm 3
D: Arm Label: ABT-450/r/ABT-267 and ABT-333, plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin | Arm Label: Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV; Type: EXPERIMENTAL; Interventions: Drug: ABT-450/r/ABT-267, ABT-333, Drug: Ribavirin, Drug: Placebo for ABT-450/r/ABT-267, Drug: Placebo for ABT-333, Drug: Placebo for ribavirin | Intervention Type: DRUG; Name: ABT-450/r/ABT-267, ABT-333; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV, Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): ABT-450/r/ABT-267 and ABT-333, plus RBV, Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ABT-450/r/ABT-267; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ABT-333; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV | Intervention Type: DRUG; Name: Placebo for ribavirin; Assigned to Arm(s): Placebo Followed by ABT-450/r/ABT-267 and ABT-333, plus RBV

Answer: C